On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading
The World Health Assembly (WHA) is the decision-making body of the WHO. The 79th meeting of the WHA was held from May 18 to May 23, 2026, in Geneva, Switzerland. Policies and decisions are largely debated and approved through two… Continue Reading
The World Health Organization (WHO) sets out the modalities to elect the successor to Dr Tedros Adhanom Ghebreyesus, whose term concludes on 15 August 2027. WHO notes: The current election process began in April 2026 when the Director-General invited Member… Continue Reading
On Friday, 22 May 2026, Knowledge Ecology International (KEI) delivered the following statement during World Health Assembly deliberations on the Reform of the global health architecture and the UN80 Initiative. 20.1 Reform of the global health architecture and the UN80… Continue Reading
On May 20, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment… Continue Reading
On Thursday, 21 May 2026, Knowledge Ecology International (KEI) will convene a side event entitled, “The future of the WHO EML and access to novel medical technologies”. The panel will take place in the Henry Dunant Room in the Henry… Continue Reading
On Monday afternoon, 4 May 2026, Knowledge Ecology International (KEI) delivered the following opening statement at the 36th session of the WIPO Committee on Development and Intellectual Property. For development, measures to address access to patented technologies are important, and… Continue Reading
U.S. legislative proposals requesting the National Academies study feasibility and benefits of delinking pharmaceutical innovation from drug prices KEI Briefing Note 2026:3 May 4, 2026 Zazie Huml KEI-BN-2026-3 Several members of Congress have asked the U.S. National Academies to study… Continue Reading
On April 20, 2026, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration” (91 FR 16205) to Perpetual Biosciences, Inc.… Continue Reading
On March 2, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention… Continue Reading